BackCogent Biosciences Overview
Cogent Biosciences Inc

Cogent Biosciences Target Price

See Cogent Biosciences's analyst price targets ($52) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$36.8

Average Target Price

$51.7540.6% upside

4 analysts in the last 4 months

High: $55 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-17Piper Sandler$5549.5% upsideOpen
2026-08-12GuggenheimMichael Schmidt$5241.3% upsideOpen
2026-06-01Stifel NicolausLaura Prendergast$4522.3% upsideOpen
2026-05-06H.C. WainwrightRobert Burns$5549.5% upsideOpen
2026-02-19Robert W. Baird$354.9% downsideOpen
2026-02-18Piper Sandler$5241.3% upsideOpen
2026-01-07UBSMichael Yee$6063% upsideOpen
2026-01-06H.C. Wainwright$5241.3% upsideOpen
2025-12-08Jefferies$4830.4% upsideOpen
2025-11-11Raymond JamesChris Raymond$6063% upsideOpen
2025-11-10Stifel Nicolaus$408.7% upsideOpen
2025-11-10WedbushDavid Nierengarten$383.3% upsideOpen
2025-10-15Stifel Nicolaus$1656.5% downsideOpen
2025-09-02Raymond James$3018.5% downsideOpen
2025-08-25Guggenheim$2045.7% downsideOpen
2025-01-14H.C. WainwrightRobert Burns$1462% downsideOpen
2024-09-24CitigroupDavid Lebowitz$1559.2% downsideOpen
2024-09-03CitigroupDavid Lebowitz$1364.7% downsideOpen
2024-09-03H.C. WainwrightRobert Burns$1753.8% downsideOpen
2024-03-30JefferiesKelly Shi$2045.7% downsideOpen
2022-12-14Needham$2434.8% downsideOpen
2022-06-17Raymond JamesChris Raymond$2240.2% downsideOpen
2022-06-10Leerink PartnersChristopher Liu$1559.2% downsideOpen

Cogent Biosciences (COGT) FAQ

Cogent Biosciences's target price stands at $52. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $52 for COGT implies 40.6% upside versus today's price ($36.8). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Cogent Biosciences's target price evolved across reporting periods, while the comparison chart places COGT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Cogent Biosciences's reading of $52 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.